NBIX vs OLN · P/E 45, rev $2.36B vs rev $6.54B
Neurocrine Biosciences Inc (NBIX) versus Olin Corporation (OLN) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Olin Corporation (OLN) is a chemicals company listed on NYSE.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported OLN revenue for 2024-12-31 was $6.54B. Net income was $105.0M. Revenue was down 4.3% from 2023-12-31 to 2024-12-31. OLN currently screens at market cap $2.62B.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. OLN currently screens at market cap $2.62B.
Not investment advice. Open the NBIX and OLN stock pages for the full models.
Not investment advice.